ReviewHematology/oncology clinics of North America2013
Immune thrombocytopenia.
Review in Hematology/oncology clinics of North America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 86 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
IL37,Tlymphocytes ,NK Cells in Pathogenesis of Immune Thrombocytopenia.
Relationship Between Different Types of COVID-19 Vaccine and Development of Immune Thrombocytopenic Purpura
Who cites it
86 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The thrombotic burden of high-risk immune thrombocytopenia patients receiving second-line treatments: a systematic review.Rheumatology (Oxford, England) · 2026Pooled it
- Evaluation ofFrontiers in medicine · 2026Pooled it
- Association of PTPN22 SNP1858 (rs2476601) and Gene SNP1123 (rs2488457) Polymorphism With Primary Immune Thrombocytopenia Susceptibility: A Meta-Analysis of Case-Control Studies and Trial Sequential Analysis.Frontiers in genetics · 2022Pooled it
- Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia.American journal of hematology · 2020Trial
- Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials.American journal of hematology · 2018Trial
- Targeting B-Cell-Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia.American journal of hematology · 2026Review
- Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I-WISh) 2.0.American journal of hematology · 2026Article
- Reactive Oxygen Species in Cardiovascular and Hematological Diseases: Mechanisms and Therapeutic Strategies.Cureus · 2026Review
- Maternal and Neonatal Outcomes of Immune Thrombocytopenia in Pregnancy: A Five-Year Single-Center Cross-Sectional Study.Health science reports · 2026Article
- Iatrogenic Kaposi Sarcoma in an HIV-Negative Patient With Immune Thrombocytopenic Purpura Treated With Rituximab and Corticosteroids: A Fatal Extracutaneous Presentation.Cancer reports (Hoboken, N.J.) · 2026Article
- Prevalence and associated factors of sexual dysfunction in female patients with immune thrombocytopenia: a longitudinal follow-up study.BMC women's health · 2026Article
- Treatment outcomes and prognostic indicators of primary immune thrombocytopenia in 31 cats: a multicenter retrospective study (2000-2023).Journal of veterinary internal medicine · 2026Article
- Association Between Bleeding Severity and Quality of Life in Adults with Immune Thrombocytopenia.Juntendo medical journal · 2026Article
- Spontaneous Lingual Bleeding and Intracerebral Hemorrhage in a Young Adult with Immune Thrombocytopenia (ITP): A Rare Case Report and Brief Recent Update on Treatment.Cardiovascular & hematological disorders drug targets · 2026Review
- Efficacy and Safety of Avatrombopag Treatment in Immune Thrombocytopenia Patients in Poland: A Multicenter Study.TH open : companion journal to thrombosis and haemostasis · 2026Article
- Immune Thrombocytopenia and Type 1 von Willebrand Disease in a Patient With a Femoral Fracture: A Case Report.Cureus · 2025Article
- Thrombocytopenia in patients with inborn errors of immunity.BMC immunology · 2025Article
- Immune thrombocytopenia as a rare initial manifestation and complication of Hodgkin lymphoma: a Pediatric case report.Oxford medical case reports · 2025Article
- Avatrombopag for the Treatment of Immune Thrombocytopenia.European journal of haematology · 2025Review
- Clinical Manifestations of Non-Congenital CMV Infection in Infants and Immunocompetent Children: Review of Cases from the Past Decade.Microorganisms · 2025Review
26 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Immune thrombocytopenia (ITP) is a common hematologic disorder characterized by isolated thrombocytopenia. ITP presents as a primary or a secondary form. ITP may affect individuals of all ages, with peaks during childhood and in the elderly, in whom the age-specific incidence of ITP is greatest. Bleeding is the most common clinical manifestation of ITP. The pathogenesis of ITP is complex, involving alterations in humoral and cellular immunity. Corticosteroids remain the most common first line therapy for ITP. This article summarizes the classification and diagnosis of primary and secondary ITP, as well as the pathogenesis and options for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.